Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 5:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 5,775 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Bronchial Disease Clear all
Terminated No phase listed Observational

Afatinib Genomic Landscape

NCT02491775
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer, Non-small Lung Cancer
Interventions
Not listed
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 5, 2018 · Synced Oct 22, 2026, 5:56 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Early Palliative Care With Standard Care or Standard Care Alone in Improving Quality of Life of Patients With Incurable Lung or Non-colorectal Gastrointestinal Cancer and Their Family Caregivers

NCT02349412
View directory record Official record
Conditions
Liver Cancer, Anxiety Disorder, Depression, Small Cell Lung Cancer, Extrahepatic Bile Duct Cancer, Malignant Mesothelioma, Pancreatic Cancer, Esophageal Cancer, Gastric Cancer, Non-small Cell Lung Cancer
Interventions
Early palliative care
Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
405 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
23
States / cities
La Jolla, California • Honolulu, Hawaii • Chicago, Illinois + 20 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2025 · Synced Oct 22, 2026, 5:56 PM EDT
Completed No phase listed Observational

Registry Study of Thoracic Reirradiation for Non-Small Cell Lung Cancer (NSCLC) Utilizing Proton Beam Therapy or Intensity Modulated Radiation Therapy

NCT01808677
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Thoracic Reirradiation Registry
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 24, 2016 · Synced Oct 22, 2026, 5:56 PM EDT
Completed No phase listed Observational

Motion Correction of Positron Emission Tomography (PET) Data Using Amplitude Gating

NCT00843219
View directory record Official record
Conditions
Lung Cancer
Interventions
PET/CT Scan
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 17, 2016 · Synced Oct 22, 2026, 5:56 PM EDT
Completed Phase 3 Interventional Results available

A Safety, Efficacy and Tolerability Study in Pediatric Subjects With Asthma

NCT00809757
View directory record Official record
Conditions
Asthma
Interventions
Levalbuterol, Levalbuterol UDV TID, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
Up to 48 Months
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
46
States / cities
Little Rock, Arkansas • Cypress, California • Long Beach, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2014 · Synced Oct 22, 2026, 5:56 PM EDT
Terminated Phase 2 Interventional Results available

S1300: Pemetrexed Disodium With or Without Crizotinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer That Has Progressed After Crizotinib

NCT02134912
View directory record Official record
Conditions
Adenocarcinoma of the Lung, Large Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions
crizotinib, pemetrexed disodium, laboratory biomarker analysis, pharmacological study
Drug · Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
167
States / cities
Sacramento, California • Aurora, Colorado • Colorado Springs, Colorado + 111 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2020 · Synced Oct 22, 2026, 5:56 PM EDT
Completed Early Phase 1 Interventional

Genomically Guided Radiation Dose Personalization in Locally Advanced NSCLC

NCT05873439
View directory record Official record
Conditions
Nonsmall Cell Lung Cancer, Nonsmall Cell Lung Cancer, Stage II, Nonsmall Cell Lung Cancer Stage III, Unresectable Non-Small Cell Lung Carcinoma
Interventions
Genomically Guided Radiation Therapy (RT)
Radiation
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 22, 2026, 5:56 PM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies

NCT04959175
View directory record Official record
Conditions
Hematologic Neoplasms
Interventions
Mycophenolate Mofetil, Allogeneic HSCT, Fludarabine, Sirolimus, Filgrastim, Cyclophosphamide, Mesna, Total Body Irradiation (TBI)
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Years to 85 Years
Enrollment
320 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
2
States / cities
Bethesda, Maryland • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 22, 2026, 5:56 PM EDT
Recruiting Phase 2 Interventional

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

NCT05642572
View directory record Official record
Conditions
Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Interventions
Biospecimen Collection, Capmatinib, Computed Tomography, Magnetic Resonance Imaging, Osimertinib, Ramucirumab
Procedure · Drug · Biological
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
454
States / cities
Daphne, Alabama • Fairhope, Alabama • Mobile, Alabama + 360 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 22, 2026, 5:56 PM EDT
Completed Phase 2 Interventional

High-dose ICE With Amifostine

NCT00003657
View directory record Official record
Conditions
Bladder Cancer, Brain and Central Nervous System Tumors, Carcinoma of Unknown Primary, Extragonadal Germ Cell Tumor, Head and Neck Cancer, Kidney Cancer, Lung Cancer, Ovarian Cancer, Sarcoma, Testicular Germ Cell Tumor, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
filgrastim, Amifostine, Carboplatin, Etoposide, Ifosfamide, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2002
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 20, 2017 · Synced Oct 22, 2026, 5:56 PM EDT
Completed Phase 1 Interventional

INC280 and Erlotinib Hydrochloride in Treating Patients With Non-small Cell Lung Cancer

NCT01911507
View directory record Official record
Conditions
Recurrent Non-small Cell Lung Cancer
Interventions
INC280, erlotinib hydrochloride
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
2
States / cities
Sacramento, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 13, 2021 · Synced Oct 22, 2026, 5:56 PM EDT
Terminated Phase 1 Interventional

A Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults With Non-Small Cell Lung Cancer

NCT04432207
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Stage IIIB, Non-small Cell Lung Cancer Stage IV, Squamous Non-small-cell Lung Cancer, Large Cell Carcinoma Lung, Adenocarcinoma Lung
Interventions
IMU-201 (administered as PD1-Vaxx) - Regimen 1, IMU-201 (administered as PD1-Vaxx) - Regimen 2, IMU-201 (administered as PD1-Vaxx) - Regimen 3, Atezolizumab, Standard of care chemotherapy
Biological · Drug
Lead sponsor
Imugene Limited
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
3
States / cities
Phoenix, Arizona • Hackensack, New Jersey • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 25, 2026 · Synced Oct 22, 2026, 5:56 PM EDT
Recruiting Not applicable Interventional

Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer

NCT05297734
View directory record Official record
Conditions
End of Life, Cancer
Interventions
Receive technology-based supportive cancer care, Receive redesigned team-based supportive cancer care
Other · Behavioral
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
2,996 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
17
States / cities
Birmingham, Alabama • Mobile, Alabama • Duarte, California + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 22, 2026, 5:56 PM EDT
Terminated Phase 4 Interventional

Childhood Asthma Research and Education (CARE) Network Trial - Montelukast or Azithromycin for Reduction of Inhaled Corticosteroids in Childhood Asthma (MARS)

NCT00471809
View directory record Official record
Conditions
Asthma
Interventions
Budesonide + Salmeterol + Azithromycin, Budesonide + Salmeterol + Montelukast, Budesonide + Salmeterol + Placebo
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
6 Years to 17 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
6
States / cities
Tucson, Arizona • Los Angeles, California • San Diego, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2016 · Synced Oct 22, 2026, 5:56 PM EDT
Completed Phase 2 Interventional Results available

Study of MAP0010 in Asthmatic Children and Adolescents

NCT00697801
View directory record Official record
Conditions
Asthma
Interventions
MAP0010 low dose, MAP0010 high dose, Placebo
Drug
Lead sponsor
Allergan
Industry
Eligibility
1 Year to 18 Years
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 9, 2014 · Synced Oct 22, 2026, 5:56 PM EDT
Completed Phase 1 Interventional

A Study of LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to Treatment

NCT05241834
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung, Thyroid Neoplasms
Interventions
LOXO-260
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
12 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
14
States / cities
Los Angeles, California • San Francisco, California • Atlanta, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 22, 2026, 5:56 PM EDT
Completed Phase 2 Interventional

Suramin, Paclitaxel, and Carboplatin in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer

NCT00006929
View directory record Official record
Conditions
Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions
suramin, carboplatin, paclitaxel, pharmacological study, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 4, 2013 · Synced Oct 22, 2026, 5:56 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Severe Asthma Research Program III-Boston Clinical Site

NCT01761630
View directory record Official record
Conditions
Asthma
Interventions
Not listed
Lead sponsor
Elliot Israel, MD
Other
Eligibility
6 Years to 60 Years
Enrollment
126 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2021
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 12, 2021 · Synced Oct 22, 2026, 5:56 PM EDT
Completed Phase 2 Interventional

Study in Patients With Asthma

NCT00215371
View directory record Official record
Conditions
Asthma
Interventions
Formoterol Fumarate
Drug
Lead sponsor
Dey
Industry
Eligibility
5 Years to 11 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
2
States / cities
Long Beach, California • Medford, Oregon
Source: ClinicalTrials.gov public record
Updated Nov 11, 2010 · Synced Oct 22, 2026, 5:56 PM EDT
Completed Phase 1 Interventional

Safety of Adding IMO-2055 to Erlotinib + Bevacizumab in 2nd Line Treatment for Patients With NSCLC

NCT00633529
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
IMO-2055
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
9
States / cities
Ocoee, Florida • Indianapolis, Indiana • Albany, New York + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2013 · Synced Oct 22, 2026, 5:56 PM EDT
Completed Not applicable Interventional Results available

Eplerenone for the Treatment of Central Serous Chorioretinopathy

NCT01990677
View directory record Official record
Conditions
Central Serous Chorioretinopathy
Interventions
25mg Eplerenone, Placebo
Drug
Lead sponsor
Wills Eye
Other
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
10
States / cities
Cherry Hill, New Jersey • Marlton, New Jersey • Mays Landing, New Jersey + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2018 · Synced Oct 22, 2026, 5:56 PM EDT
Terminated Phase 1 Interventional

A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.

NCT03549000
View directory record Official record
Conditions
Non-small Cell Lung Cancer (NSCLC), Triple Negative Breast Cancer (TNBC), Pancreatic Ductal Adenocarcinoma (PDAC), Colorectal Cancer Microsatellite Stable (MSS), Ovarian Cancer, Renal Cell Carcinoma (RCC), Metastatic Castration Resistant Prostate Cancer (mCRPC)
Interventions
NZV930, PDR001, NIR178
Other · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
2
States / cities
Tampa, Florida • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 13, 2024 · Synced Oct 22, 2026, 5:56 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Exploring the Effects of Sleep Patterns and Physical Activity on Asthma in Adolescents With Wrist-worn Smart Devices

NCT02556567
View directory record Official record
Conditions
Asthma
Interventions
Fitbit® Charge Heart Rate (HR) wristband
Other
Lead sponsor
Arkansas Children's Hospital Research Institute
Other
Eligibility
14 Years to 17 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jul 31, 2024 · Synced Oct 22, 2026, 5:56 PM EDT
Completed Phase 3 Interventional Results available

A Study of the Safety and Effectiveness of Benralizumab to Treat Patients With Severe Uncontrolled Asthma.

NCT03170271
View directory record Official record
Conditions
Asthma
Interventions
Benralizumab (Medi-563), Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
660 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
100
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 87 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 22, 2026, 5:56 PM EDT